News - Boehringer Ingelheim, Pricing

Filter

Popular Filters

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

UK NICE recommends Giotrif and Velcade, but says “no” to added use of Alimta

23-04-2014

People in England and Wales with lung cancer whose tumors test positive for a mutation will now have…

AlimtaBoehringer IngelheimEli LillyGiotrifJohnson & JohnsonNorthern EuropeOncologyPharmaceuticalPricingRegulationUKVelcade

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

NICE draft guidance recommends Boehringer Ingelheim’s Giotrif

17-03-2014

UK drugs watchdog the National Institute for Health and care Excellence (NICE) this morning issued new…

Boehringer IngelheimGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulationUK

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

IQWiG finds that added benefit of Boehringer’s Giotrif depends on mutation status

19-02-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG), in an early benefit assessment…

Boehringer IngelheimGermanyGiotrifNorthern EuropeOncologyPharmaceuticalPricingRegulation

Pharma giants included in China's investigation into pricing of foreign imports

05-07-2013

China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

Australian review finds more work needed on new anticoagulants

19-12-2012

A report into anticoagulation therapies released yesterday by Australian Minister for Health Tanya Plibersek…

Asia-PacificBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulation

Once again, no proof of added benefit found for Boehringer/Lilly's Trajenta by Germany's IQWiG

13-12-2012

Once again, the German Institute for Quality and Efficiency in Health Care (IQWiG) has found no added…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalPricingRegulationTrajenta

Study attacks Pharma business practices in Brazil

11-12-2012

A study reported by broadcaster Deutsche Welle on the business practices of drug companies Bayer, Baxter…

BaxterBayerBoehringer IngelheimMarkets & MarketingPharmaceuticalPricingSouth America

NICE final guidance backs NHS use of Boehringer Ingelheim's Actilyse

25-09-2012

In final guidance issued this morning (September 26), UK drugs watchdog the National Institute for Health…

ActilyseBoehringer IngelheimCardio-vascularEuropePharmaceuticalPricingRegulation

Pradaxa efficacy and cost effectiveness advantages over Xarelto

27-08-2012

Indirect comparison based on the RE-LYtrial (for family owned German drugmaker Boehringer Ingelheim's…

BayerBoehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingResearchXarelto

NICE recommends NHS use of Pradaxa

15-03-2012

In final guidance published today (March 15), the UK drug watchdog the National Institute of Health and…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

UK ABPI gears up for next pricing negotiations; Boehringer breaches code

19-12-2011

The Associations of the British Pharmaceutical Association (ABPI) last Friday brought together pharmaceutical…

Boehringer IngelheimEuropeMarkets & MarketingPharmaceuticalPradaxaPricing

UK NICE recommends Boehringer’s Pradaxa for stroke prevention

01-11-2011

In final draft guidance published today (November 1), the UK’s drug watchdog the National Institute…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaPricingRegulation

Benefits of Boehringer’s Pradaxa come at high cost, study finds

20-10-2011

Treating patients with the new blood thinning medication dabigatran (German independent drug major Boehringer…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaPricing

Australian government U-turn on PBS listing of drugs

03-10-2011

More than 160,000 Australians per year will benefit from the Australian Government’s decision to…

Asia-PacificBoehringer IngelheimPharmaceuticalPradaxaPricingRegulation

AIDS drugmakers’ charity programs fail patients, yet provide millions in tax breaks to industry, AHF accuses, but applauds Boehringer

03-08-2011

The USA-based AIDS Healthcare Foundation (AHF) is, in its own words, “blowing the whistle”…

Boehringer IngelheimFinancialGilead SciencesNorth AmericaPharmaceuticalPricing

Back to top